{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:39:49Z","timestamp":1787312389733,"version":"build-2736575974"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Inflammatory bowel disease (IBD), including ulcerative colitis and Crohn\u2019s disease, is a group of chronic intestinal inflammatory diseases. Its incidence and prevalence have been on the rise globally, imposing a heavy burden on patients\u2019 health and social medical resources. Intestinal microbiota dysbiosis is believed to play a crucial role in the occurrence and development of IBD, but the association between them and the global disease burden growth trend remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      By searching the Global Burden of Disease (GBD) study database, we collected IBD disease burden data from 180 countries and regions between 1990 and 2023, including key indicators such as incidence, prevalence, mortality, and disability-adjusted life years (DALYs). Intestinal microbiota data were sourced from two parts: (1) Independent collection: A total of 20,000 healthy individuals and IBD patients were selected as research subjects from 180 countries and regions using a stratified random sampling method. Fecal samples (2\u20135 grams per person) were collected and immediately stored in a \u221280 \u00b0C ultra-low temperature refrigerator to avoid changes in the microbial community structure; (2) Supplementary data from public databases: Published intestinal microbiota sequencing data of corresponding regions from 1990 to 2023 were extracted from the MGnify (\n                      <jats:uri>https:\/\/www.ebi.ac.uk\/metagenomics\/<\/jats:uri>\n                      ), Human Microbiome Project (HMP), and GMrepo (\n                      <jats:uri>https:\/\/gmrepo.humangut.info\/<\/jats:uri>\n                      ) databases. The sample size for each country and region was no less than 500 to cover populations of different ages (18\u201370\u202fyears), genders (male\/female ratio approximately 1:1), and dietary habits (high-fiber diet, high-sugar and high-fat diet). Technologies like metagenomic sequencing and 16S rRNA gene sequencing were used to obtain data on the composition, abundance, and diversity of the intestinal microbiota of the corresponding regional populations. For metagenomic sequencing, the Illumina HiSeq or NovaSeq platform was used. Linear regression models, time-series analysis, and causal inference methods were applied to evaluate the correlation between intestinal microbiota dysbiosis and the growth trends of various disease burden indicators, and to explore the potential impact mechanisms.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The global incidence of IBD increased from 12.3 per 100,000 in 1990 to 25.6 per 100,000 in 2023, the prevalence rose from 396 per 100,000 to 523 per 100,000, and the DALY value also increased significantly (from 230 per 100,000 in 1990 to 380 per 100,000 in 2023). The average annual growth rates of the above indicators were 2.8% (95% CI: 2.5\u20133.1%,\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt;\u202f0.001), 1.0% (95% CI: 0.8\u20131.2%,\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt;\u202f0.001), and 1.5% (95% CI: 1.3\u20131.7%,\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt;\u202f0.001), respectively. Further analysis showed that intestinal microbiota dysbiosis was closely related to the growth of the disease burden. In regions with severe microbiota dysbiosis, the annual growth rate of the IBD incidence was 3.2 times higher than that in balanced regions (\n                      <jats:italic>\u03b2<\/jats:italic>\n                      =\u202f3.2, 95% CI: 2.8\u20133.6,\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt;\u202f0.001); when the average abundance of beneficial bacteria such as\n                      <jats:italic>Bifidobacterium<\/jats:italic>\n                      and\n                      <jats:italic>Lactobacillus<\/jats:italic>\n                      in the intestine decreased by 40% (relative to the average abundance of healthy populations) and the abundance of harmful bacteria such as\n                      <jats:italic>Escherichia coli<\/jats:italic>\n                      increased by 60%, the annual growth rate of IBD incidence in this region was as high as 8.5% (95% CI: 7.9\u20139.1%,\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt;\u202f0.001); in regions where the Shannon index decreased by 10%, the incidence of IBD increased by an average of 15% (\n                      <jats:italic>\u03b2<\/jats:italic>\n                      =\u202f0.15, 95% CI: 0.12\u20130.18,\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt;\u202f0.001). A positive correlation was observed between the degree of intestinal microbiota dysbiosis and disease severity (measured by DALYs): in regions where the intestinal F\/B ratio deviated from the normal range by more than 30%, DALYs were 40% higher than those in regions with a normal ratio (\n                      <jats:italic>\u03b2<\/jats:italic>\n                      =\u202f0.40, 95% CI: 0.35\u20130.45,\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt;\u202f0.001); in regions where the content of short-chain fatty acids (SCFAs) decreased by 20%, DALYs increased by approximately 25% (\n                      <jats:italic>\u03b2<\/jats:italic>\n                      =\u202f0.25, 95% CI: 0.21\u20130.29,\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt;\u202f0.001). Among IBD patients with different severity levels in the Asian region, the abundance of specific bacterial genera related to inflammation regulation (e.g.,\n                      <jats:italic>Faecalibacterium<\/jats:italic>\n                      ) in the intestines of severe patients decreased by more than 50% compared with healthy populations, and their DALY values were 60% higher than those of mild patients (95% CI: 55\u201365%,\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt;\u202f0.001). Additionally, the SCFA levels of severe patients were significantly lower than those of mild patients and healthy populations (median SCFA level: 2.1\u202fmmol\/L in severe patients; 4.5\u202fmmol\/L in mild patients; 6.8\u202fmmol\/L in healthy populations,\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt;\u202f0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study confirms a close association between intestinal microbiota dysbiosis in inflammatory bowel disease and the global disease burden growth trend. Intestinal microbiota dysbiosis can be used as a key indicator to predict the growth of the IBD disease burden, providing an important theoretical basis for formulating targeted prevention, control strategies, and treatment methods.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2025.1635242","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T06:35:22Z","timestamp":1764138922000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Association study between intestinal microbiota dysbiosis in inflammatory bowel disease and the global disease burden growth trend"],"prefix":"10.3389","volume":"12","author":[{"given":"Xiawei","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gengzhao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qilin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longqin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1053\/j.gastro.2021.12.282","article-title":"Twenty-first century trends in the global epidemiology of pediatric-onset inflammatory bowel disease: systematic review","volume":"162","author":"Kuenzig","year":"2022","journal-title":"Gastroenterology"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"e065186","DOI":"10.1136\/bmjopen-2022-065186","article-title":"Global, regional and national burden of inflammatory bowel disease in 204 countries and territories from 1990 to 2019: a systematic analysis based on the Global Burden of Disease Study 2019","volume":"13","author":"Wang","year":"2023","journal-title":"BMJ Open"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/S2468-1253(21)00014-5","article-title":"Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"6","author":"Barberio","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"103498","DOI":"10.1016\/j.autrev.2023.103498","article-title":"Global, regional, and national burden of inflammatory bowel disease and its associated anemia, 1990 to 2019 and predictions to 2050: an analysis of the Global Burden of Disease Study 2019","volume":"23","author":"Wang","year":"2024","journal-title":"Autoimmun Rev"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1002\/ueg2.12317","article-title":"Implications of the changing epidemiology of inflammatory bowel disease in a changing world","volume":"10","author":"Agrawal","year":"2022","journal-title":"United European Gastroenterol J"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"3817","DOI":"10.3390\/ijms24043817","article-title":"Inflammatory bowel diseases and gut microbiota","volume":"24","author":"Haneishi","year":"2023","journal-title":"Int J Mol Sci"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"733992","DOI":"10.3389\/fcimb.2022.733992","article-title":"The gut microbiota in inflammatory bowel disease","volume":"12","author":"Qiu","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"4053","DOI":"10.3748\/wjg.v28.i30.4053","article-title":"Gut microbiota, inflammatory bowel disease and colorectal cancer","volume":"28","author":"Quaglio","year":"2022","journal-title":"World J Gastroenterol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41575-019-0258-z","article-title":"Gut microbiota-derived metabolites as key actors in inflammatory bowel disease","volume":"17","author":"Lavelle","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1146\/annurev-med-042320-021020","article-title":"The gut microbiome and inflammatory bowel diseases","volume":"73","author":"Shan","year":"2022","journal-title":"Annu Rev Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1136\/gutjnl-2023-330001","article-title":"Gut virome in inflammatory bowel disease and beyond","volume":"73","author":"Tun","year":"2024","journal-title":"Gut"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"6242","DOI":"10.3390\/ijms22126242","article-title":"Interaction between lipopolysaccharide and gut microbiota in inflammatory bowel diseases","volume":"22","author":"Candelli","year":"2021","journal-title":"Int J Mol Sci"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1038\/s41423-021-00661-4","article-title":"Gut microbiota-derived metabolites in the regulation of host immune responses and immune-related inflammatory diseases","volume":"18","author":"Yang","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"102319","DOI":"10.1016\/j.mib.2023.102319","article-title":"Targeting the gut microbiota in inflammatory bowel diseases: where are we?","volume":"74","author":"Benech","year":"2023","journal-title":"Curr Opin Microbiol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3389\/fimmu.2018.00072","article-title":"Toll-like receptors and inflammatory bowel disease","volume":"9","author":"Lu","year":"2018","journal-title":"Front Immunol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"567","DOI":"10.3390\/medicina58050567","article-title":"Inflammatory bowel disease: clinical diagnosis and surgical treatment-overview","volume":"58","author":"M\u2019Koma","year":"2022","journal-title":"Medicina"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1132306","DOI":"10.3389\/fonc.2023.1132306","article-title":"Risk factors for early-onset colorectal cancer: systematic review and meta-analysis","volume":"13","author":"Hua","year":"2023","journal-title":"Front Oncol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1968257","DOI":"10.1080\/19490976.2021.1968257","article-title":"Microbiota metabolite butyrate constrains neutrophil functions and ameliorates mucosal inflammation in inflammatory bowel disease","volume":"13","author":"Li","year":"2021","journal-title":"Gut Microbes"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1186\/s12967-024-05058-1","article-title":"Predictive biomarkers for anti-TNF alpha therapy in IBD patients","volume":"22","author":"Kumar","year":"2024","journal-title":"J Transl Med"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"3114","DOI":"10.3390\/nu15143114","article-title":"High-fiber diet and Crohn\u2019s disease: systematic review and meta-analysis","volume":"15","author":"Serrano Fernandez","year":"2023","journal-title":"Nutrients"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"9588","DOI":"10.3390\/ijms23179588","article-title":"Influence of foods and nutrition on the gut microbiome and implications for intestinal health","volume":"23","author":"Zhang","year":"2022","journal-title":"Int J Mol Sci"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1016\/j.csbj.2022.03.038","article-title":"Gut microbial metabolome in inflammatory bowel disease: from association to therapeutic perspectives","volume":"20","author":"Li","year":"2022","journal-title":"Comput Struct Biotechnol J"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.3389\/fimmu.2020.02144","article-title":"Links between inflammatory bowel disease and chronic obstructive pulmonary disease","volume":"11","author":"Raftery","year":"2020","journal-title":"Front Immunol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3390\/nu13010135","article-title":"The role of diet in the pathogenesis and management of inflammatory bowel disease: a review","volume":"13","author":"Wark","year":"2020","journal-title":"Nutrients"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1093\/ibd\/izab335","article-title":"Dietary patterns and their association with symptoms activity in inflammatory bowel diseases","volume":"28","author":"Limketkai","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.3748\/wjg.v28.i18.1875","article-title":"Gut microbiota in various childhood disorders: implication and indications","volume":"28","author":"Saeed","year":"2022","journal-title":"World J Gastroenterol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"2211501","DOI":"10.1080\/19490976.2023.2211501","article-title":"Dietary palmitoleic acid reprograms gut microbiota and improves biological therapy against colitis","volume":"15","author":"Chen","year":"2023","journal-title":"Gut Microbes"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"174","DOI":"10.26574\/maedica.2023.18.2.174","article-title":"Impact of dietary patterns in inflammatory bowel disease subtypes versus healthy subjects: a retrospective cohort study","volume":"18","author":"Preda","year":"2023","journal-title":"Maedica"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"8805","DOI":"10.1080\/10408398.2023.2204147","article-title":"A critical review on inflammatory bowel diseases risk factors, dietary nutrients regulation and protective pathways based on gut microbiota during recent 5 years","volume":"64","author":"Xia","year":"2024","journal-title":"Crit Rev Food Sci Nutr"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1093\/ibd\/izad297","article-title":"Dietary patterns and risk of inflammatory bowel disease: a systematic review of observational studies","volume":"30","author":"Khademi","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"5426","DOI":"10.3390\/molecules28145426","article-title":"Anti-inflammatory effects of dietary polyphenols through inhibitory activity against metalloproteinases","volume":"28","author":"Suzuki","year":"2023","journal-title":"Molecules"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"5680","DOI":"10.1039\/D3FO04919A","article-title":"Research progress in the treatment of inflammatory bowel disease with natural polysaccharides and related structure-activity relationships","volume":"15","author":"Chen","year":"2024","journal-title":"Food Funct"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.gastrohep.2022.10.005","article-title":"Perception of the need for dietary advice and dietary modifications in inflammatory bowel disease patients","volume":"46","author":"Gely","year":"2023","journal-title":"Gastroenterol Hepatol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.3390\/ijms25021311","article-title":"Intestinal inflammation and regeneration-interdigitating processes controlled by dietary lipids in inflammatory bowel disease","volume":"25","author":"Kwon","year":"2024","journal-title":"Int J Mol Sci"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"109238","DOI":"10.1016\/j.jnutbio.2022.109238","article-title":"Interplay of broccoli\/broccoli sprout bioactives with gut microbiota in reducing inflammation in inflammatory bowel diseases","volume":"113","author":"Holman","year":"2023","journal-title":"J Nutr Biochem"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.ijbiomac.2022.03.218","article-title":"Inulin fructans in diet: role in gut homeostasis, immunity, health outcomes and potential therapeutics","volume":"208","author":"Tawfick","year":"2022","journal-title":"Int J Biol Macromol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1016\/j.cell.2025.01.045","article-title":"Functional diversification of dietary plant small molecules by the gut microbiome","volume":"188","author":"Kuziel","year":"2025","journal-title":"Cell"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"105694","DOI":"10.1016\/j.phrs.2021.105694","article-title":"Main active components of Jiawei Gegen Qinlian decoction protects against ulcerative colitis under different dietary environments in a gut microbiota-dependent manner","volume":"170","author":"Li","year":"2021","journal-title":"Pharmacol Res"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"142932","DOI":"10.1016\/j.foodchem.2025.142932","article-title":"Advances in dietary polyphenols: regulation of inflammatory bowel disease (IBD) via bile acid metabolism and the gut-brain axis","volume":"472","author":"Jiang","year":"2025","journal-title":"Food Chem"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1635242\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T06:35:23Z","timestamp":1764138923000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1635242\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":40,"alternative-id":["10.3389\/fmed.2025.1635242"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1635242","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"article-number":"1635242"}}